Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Journal of Surgical Education|April 16, 2025
Evaluation of a Cost-Effective Virtual Reality Training System in Oral Maxillofacial Surgery: A Pilot StudySeongwon Choi, Daniel Oh, Hyunwook Ham, et al.
Clinical Pharmacology and Therapeutics|June 28, 2024
Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T-Cell Engager, Using Population Pharmacokinetics and Exposure-Response AnalysisBrian Kiesel, Mayu Osawa, Madhan Masilamani, et al.
JAMA Neurology|May 23, 2024
Early Access to First-Seizure Clinics, Subsequent Outcomes, and Factors Associated With AttendanceYingtong Li, Tianrui Ren, Michael Burgess, et al.
British Journal of Clinical Pharmacology|July 10, 2003
A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979)Sophie Callies, Dinesh P de Alwis, Adrian Harris, et al.
Epilepsia|November 28, 2023
Long-term physical and psychiatric morbidities and mortality of untreated, deferred, and immediately treated epilepsyTianrui Ren, Yingtong Li, Michael Burgess, et al.
Molecular & Cellular Proteomics : MCP|July 15, 2009
Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilutionHasmik Keshishian, Terri Addona, Michael Burgess, et al.
Clinical Chemistry|April 18, 2009
Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometryEric Kuhn, Terri Addona, Hasmik Keshishian, et al.
Cell Chemical Biology|April 9, 2021
Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting ChimerasKusal T G Samarasinghe, Saul Jaime-Figueroa, Michael Burgess, et al.
Haematologica|July 20, 2004
Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabineGareth Gerrard, Elspeth Payne, Robert J Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancyAlan Sandler, Michael Gordon, Dinesh P De Alwis, et al.
Pageof 6